Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 469 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stage IV Non-Small Cell Lung Cancer AJCC v7 Clear all
Completed Phase 2 Interventional

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00276588
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00287989
View directory record Official record
Conditions
Lung Cancer
Interventions
Carboplatin, erlotinib hydrochloride, Paclitaxel
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)

NCT03840915
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cisplatin, Carboplatin, Pemetrexed, Nab-paclitaxel, Gemcitabine, Docetaxel, M7824, Bintrafusp alfa, Paclitaxel
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Fountain Valley, California • San Marcos, California • Port Saint Lucie, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 2 Interventional

Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00305786
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine hydrochloride, oxaliplatin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer

NCT00986674
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cixutumumab, carboplatin, paclitaxel, cetuximab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
249
States / cities
Stanford, California • Aurora, Colorado • Boulder, Colorado + 171 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2014 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 2 Interventional

Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00098540
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
sorafenib tosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 13, 2026, 9:41 PM EDT
Terminated Phase 1 Interventional

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

NCT05631574
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Goodyear, Arizona • Encinitas, California • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 13, 2026, 9:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy

NCT00534209
View directory record Official record
Conditions
Lung Cancer
Interventions
Allogeneic B7.1/HLA-A1, Placebo
Biological · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Hollywood, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 1 Interventional

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

NCT02592577
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Carcinoma
Interventions
Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T
Biological
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
14
States / cities
Duarte, California • Palo Alto, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 13, 2026, 9:41 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

NCT04285671
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Necitumumab, Osimertinib, Quality-of-Life Assessment, Questionnaire Administration, Trastuzumab
Biological · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 1 Interventional

Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00857025
View directory record Official record
Conditions
Lung Cancer
Interventions
beta-glucan MM-10-001, flow cytometry, laboratory biomarker analysis, questionnaire administration
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

NCT00005850
View directory record Official record
Conditions
Anxiety Disorder, Depression, Fatigue, Lung Cancer
Interventions
cisplatin, fluoxetine, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
42
States / cities
Anniston, Alabama • San Diego, California • Washington D.C., District of Columbia + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 1 Interventional

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

NCT02503358
View directory record Official record
Conditions
Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Selumetinib
Other · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 13, 2026, 9:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC

NCT00544648
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, nab-paclitaxel, Radiation therapy
Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Paducah, Kentucky • Portland, Oregon • Chattanooga, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 2 Interventional

Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer

NCT00059943
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Prostate Cancer
Interventions
docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00454194
View directory record Official record
Conditions
Lung Cancer
Interventions
pemetrexed disodium, sorafenib tosylate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
207
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 124 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 13, 2026, 9:41 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants

NCT00444223
View directory record Official record
Conditions
Lung Cancer
Interventions
fluorine F 18 FEQA + positron emission tomography
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 13, 2026, 9:41 PM EDT
Withdrawn Phase 1Phase 2 Interventional

CISH Inactivated TILs in the Treatment of NSCLC

NCT05566223
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
Interventions
Fludarabine, Cyclophosphamide, CISH Inactivated TIL, Aldesleukin, Pembrolizumab
Drug · Biological
Lead sponsor
Intima Bioscience, Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Duarte, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 2 Interventional

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00072059
View directory record Official record
Conditions
Anemia, Lung Cancer
Interventions
methoxy polyethylene glycol epoetin beta
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer

NCT02417701
View directory record Official record
Conditions
Recurrent Lung Squamous Cell Carcinoma, Stage IV Lung Squamous Cell Carcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00481078
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
vorinostat, paclitaxel, carboplatin, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 3 Interventional Results available

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

NCT03215706
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Ipilimumab, Nivolumab, Carboplatin, Paclitaxel, Pemetrexed, Cisplatin
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
16
States / cities
Colorado Springs, Colorado • Plainville, Connecticut • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 13, 2026, 9:41 PM EDT
Completed No phase listed Observational

Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy

NCT00450567
View directory record Official record
Conditions
Lung Cancer
Interventions
computed tomography, positron emission tomography, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 13, 2026, 9:41 PM EDT
Completed Phase 1 Interventional

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

NCT00005842
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 13, 2026, 9:41 PM EDT